Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge

Clinical Therapeutics

Volumn 24, Issue 7, 2002, Pages 1161-1174

  Lanier, Bob Q ^a   Abelson, Mark B ^b   Berger, William E ^c,d   Granet, David B ^e   D'Arienzo, Peter A ^f   Spangler, Dennis L ^g   Kägi, Martin K ^h  

^a Fort Worth Allergy Asthma Association   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Southern California Research   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Catholic Medical Center of Brooklyn   (United States)

^g Atlanta Allergy and Asthma Clinic   (United States)

^h Dermatology Allergy and Immunology FMH   (Switzerland)

Author keywords

Conjunctival allergen challenge; Fexofenadine; Fluticasone; Ocular allergy; Olopatadine

Indexed keywords

ALLERGEN; FEXOFENADINE; FLUTICASONE; FLUTICASONE PROPIONATE; NAPHAZOLINE; OLOPATADINE; TEARS NATURALE; TETRYZOLINE; ANDROSTANE DERIVATIVE; ANTIALLERGIC AGENT; ANTIINFLAMMATORY AGENT; DIBENZOXEPIN DERIVATIVE; DRUG DERIVATIVE; EYE DROPS; HISTAMINE H1 RECEPTOR ANTAGONIST; TERFENADINE;

ADULT; ALLERGIC CONJUNCTIVITIS; ALLERGIC REACTION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EYE DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PRURITUS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; STANDARDIZATION; SYMPTOM; TREATMENT OUTCOME; DRUG COMBINATION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; PERENNIAL RHINITIS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, TOPICAL; ADULT; ALLERGENS; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; CONJUNCTIVITIS, ALLERGIC; DIBENZOXEPINS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; OPHTHALMIC SOLUTIONS; RHINITIS, ALLERGIC, PERENNIAL; TERFENADINE; TREATMENT OUTCOME;

EID: 0036022903     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80027-3     Document Type: Article

References (19)

1. Allergic rhinoconjunctivitis - An overview
2. Acute allergic conjunctivitis
3. The ocular drying effect of oral antihistamines (loratadine) in the normal population: An evaluation
4. Intranasal steroids inhibit seasonal increases in ragweed-specific immunoglobulin E antibodies
5. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge
6. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis
7. Treatment of urticaria. An evidence-based evaluation of antihistamines
8. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model
9. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model
10. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis
11. Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions
12. 1-receptor antagonists assessed by nasal challenge
13. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms
14. A quantitative analysis of the intranasal delivery of topical nasal drugs to the middle meatus: Spray versus drop administration
15. Distribution and clearance of radioactive aerosol on the nasal mucosa
16. Patanol is effective in the treatment of the signs and symptoms of allergic conjunctivitis and allergic rhinoconjunctivitis
17. An evaluation of onset and duration of action of Patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model
18. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic disease